Article Per Year (5 Year)
p-Index From 2021 - 2026
2.092
P-Index
This Author published in this journals
All Journal Jurnal Kesehatan Masyarakat AKSIOLOGIYA : Jurnal Pengabdian Kepada Masyarakat Journal of Midwifery and Nursing JCPS (Journal of Current Pharmaceutical Sciences) Pharmacoscript Jurnal Ilmu Kesehatan Science Midwifery Kartika : Jurnal Ilmiah Farmasi
Oskar Skarayadi, Oskar
Fakultas Farmasi Universitas Jenderal Achmad Yani
Chemistry Dentistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Nursing Public Health Social Sciences Veterinary

Published : 14 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search
Journal : Science Midwifery

 1 
Differences in the Use of Covid-19 Comorbid Drugs in Before and Early Of Pandemic Oskar Skarayadi; Syarifuddin; M.Robby Ramdhani; M Rifky Rohman; Arif R Sjahidy
Science Midwifery Vol 10 No 5 (2022): December: Science Midwifery
Publisher : Institute of Computer Science (IOCS)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35335/midwifery.v10i5.928

Abstract

Comorbid patients with Covid 19 affect the severity of the infection. This study aims to examine the utilization of generic medications in the treatment of comorbid Covid-19. Data were retrieved retrospectively from Al Ihsan Hospital's medical records. The data summarize the use of generic medicines for comorbid Covid-19 in the year preceding and in the first year of the pandemic. Metformin is the most commonly recommended medication for type 2 diabetes management.In contrast, Acarbose was the most extensively used medicine before the epidemic. Pioglitazone is the least prescribed diabetes medication. Before the pandemic, Amlodipine 10 mg was the most commonly prescribed medication for cardiovascular disease management. This is distinct from the pre-pandemic period when Ramipril was the most frequently used medication. Verapamil was the least prescribed medication prior to and throughout the epidemic. Three of the eleven medicine names analyzed in the Diabetes Comorbid group indicated that there was a significant variation in use between before and during the pandemic. Thirteen of the twenty-one medicine names analyzed in the Cardiovascular Comorbid group showed a substantial variation in usage between before and during a pandemic.
Cost effectiveness analysis of rheumatoid arthritis outpatient at a hospital in bandung Oskar Skarayadi; Wita Anggraeni; Pudjiastuti Kartidjo; Andri Reza Rahmadi; Suci Nar Vikasari
Science Midwifery Vol 10 No 6 (2023): February: Midwifery and Health Sciences
Publisher : Institute of Computer Science (IOCS)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35335/midwifery.v10i6.1155

Abstract

Rheumatoid arthritis is a chronic systemic autoimmune disease of the joints with unknown etiology. treatment therapy is carried out to reduce the symptoms of inflammation, one of which is by using methylprednisolone and methotrexate. treatment is carried out in the long term. this study aims to analyze the cost-effectiveness of combined methylprednisolone in rheumatoid arthritis patients. the study used a retrospective descriptive analytic design. the data were taken from 31 outpatient medical records in hasan sadikin hospital from january 2017-december 2018. the research data included the das28 score, doctor visit fees, medical expenses, and laboratory fees. cost-effectiveness analysis is done by calculating the average cost effectiveness ratio (acer) and incremental cost effectiveness ratio (icer). the results showed 17 patients using methylprednisolone+methotrexate, 6 patients using methylprednisolone+sulfasalazine, 1 patient using methylprednisolone+cyclosporine, 2 patients using methylprednisolone+methotrexate+chloroquine, 3 patients using methylprednisolone+chloroquine+cyclosporine and 2 patients using methylprednisolone+chloroquine. the lowest acer value was obtainedwhen the combination of methylpredisolone+chloroquine was rp. 453,716 per effectiveness with an icer value of rp. 11,686 per effectiveness. this study concludes that the combination of methylprednisolone + chloroquine is the most effective therapy compared to other combinations of methylprednisolone.
Cost of illness coronavirus disease 2019 (covid-19) with comorbidities in a hospital in west java Alfi Nurul Islamiyah; Oskar Skarayadi; Nur Hafidah Turrahmat; Siti Susiani
Science Midwifery Vol 10 No 6 (2023): February: Midwifery and Health Sciences
Publisher : Institute of Computer Science (IOCS)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35335/midwifery.v10i6.1179

Abstract

Epidemiological evidence has suggested that individuals with chronic disease may have a 10-fold risk of developing severe COVID-19 disease compared to individuals without comorbidities. The analysis that estimates the cost of treating COVID-19 patients is still very limited, especially in Indonesia. Thus, in this study, disease costs will be carried out to analyze the costs of clinical management of COVID-19 in patients with comorbidities during hospitalization. This study is a descriptive study using the economy evaluation method, in which the burden of the economy of the COVID-19 disease is included in the direct costs. Sampling was carried out with a purposive sampling method in inpatient COVID-19 patients who had comorbidities at a hospital in West Java during the second wave of COVID-19 in Indonesia (June, July, and August 2021). Ninety-six patients were diagnosed with COVID-19 with comorbid CAP and comorbid Type 2 DM, whose cost data were evaluated with the cost of illness. The total cost of COVID-19 patients with comorbid CAP is Rp. 1,773,944,688 with an average cost of Rp. 25,342,067 ± 10,550,734, and comorbid type 2 diabetes is Rp. 782,391,792 with an average cost of Rp. 30,091,992 ± 14,773,533. The average length of stay for COVID-19 patients with comorbid CAP was 10.1 ± 3.6 days, and comorbid type 2 DM was 11.3 ± 4.5 days. These results indicate that COVID-19 with comorbidities provides a considerable burden on patients, increases the length of treatment for patients, and is quite expensive.
Co-Authors Adirestuti, Putranti Afifah B Sutjiatmo Alfi Nurul Islamiyah Ambarsundari Ambarsundari Ambarsundari Ambarsundari Ambarsundari, Ambarsundari Andri Reza Rahmadi Anggraini, Salmah Wilujeng Anisar Arif R Sjahidy Duda, Melkyanto Dzikrial Sa’id Eka Kartika Untari Elvan Arsyad Aulia Endah Wahyuni Hartyana Sutarna, Titta Indriyati, Silvia Kharina M Rifky Rohman M.Robby Ramdhani Made Pasek Narendra Maryani, Nura Sela Mega Mutiana Melkyanto Duda Muhammad Didit Prasodjo Muhardianti, Siti Narendra, Made Pasek Niken Larasati Ningrum, Dyah Puspita Nur Hafidah Turrahmat Octaviani, Peppy Pratama, Muhammad Ihsan Pudjiastuti Kartidjo Pudjiastuti Kartidjo, Pudjiastuti Purwoko, Agus Puspa Sari Dewi, Puspa Sari Putranti Adirestuti Putri, Belia Destama Rahmadani, Bella Nur Aulia Ramadhan Muhamad Syahrul Robby Ramdani Sari, Velia Yunita Siska, Dede Siti Susiani Suci Nar Vikasari, Suci Nar Sutandi Tatan Syarifuddin Syarifuddin Syarifuddin Syarifudin Syarifudin Wita Anggraeni Wiwiek Indrawati